Skip to main content
. 2013 May 31;11:134. doi: 10.1186/1479-5876-11-134

Table 3.

Adverse events during the follow-up period

  TwHF group (n = 34) Valsartan group (n = 31)
Any adverse event (n,%)
13 (38.3)
12 (38.7)
Vomiting (n,%)
1 (2.94)
0 (0.00)
Liver dysfunction (n,%)
3 (8.82)
0 (0.00)
Decrease in WBC count (n,%)
1 (2.94)
0 (0.00)
Photosensitive dermatitis (n,%)
0 (0.00)
1 (3.22)
Hyperkalemia (n,%)
8 (23.53)
10 (32.2)
K+ > 6.0 (n,%)
3 (8.82)
2 (6.45)
Doubling of serum creatinine (n,%) 0 (0.00) 1 (3.22)